Linc invests in product oriented companies in the Nordic Life Science industry. We mainly invest in and develop small and medium-sized product oriented life science companies in Medical Technology and Pharmaceuticals.
The investments are made in both private and public companies and in research and operational companies. Typically, investments in drug development take place in an early phase compared with investments in medical technology.
Linc is an active and long-term owner with a broad industrial network to support the portfolio companies. We work together with management, founders and the board to realize the inherent potential that exists in the company, have ambitious plans for further development and expansion and actively participate in the nomination committee’s work.
At the end of 2021, Linc had a NAV (net asset value) of about SEK 3.6 billion.